-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Cerevel Therapeutics Holdings, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q1 2024.
- Cerevel Therapeutics Holdings, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$143M, a 43.3% decline year-over-year.
- Cerevel Therapeutics Holdings, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$490M, a 24.2% decline year-over-year.
- Cerevel Therapeutics Holdings, Inc. annual Operating Income (Loss) for 2023 was -$447M, a 21.6% decline from 2022.
- Cerevel Therapeutics Holdings, Inc. annual Operating Income (Loss) for 2022 was -$368M, a 67.1% decline from 2021.
- Cerevel Therapeutics Holdings, Inc. annual Operating Income (Loss) for 2021 was -$220M, a 47.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)